| Filed On | Filing |
|---|---|
| 09 Oct 2026 | EFFECT |
| 08 Oct 2026 | D |
| 02 Oct 2026 | S-1 |
| 01 Oct 2026 | Proxy statement: special meeting on November 17, 2026 |
| 24 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more
This Securities Purchase Agreement (this “Agreement”) is entered into and made effective as of September 23, 2026, by and among HCW Biologics Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages ... |
| 10 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
On September 9, 2026, HCW Biologics Inc. issued Amendment No. 1 to Preliminary Proxy Statement, a copy of which is included in this Form 8-K as Exhibit 10.1. |
| 09 Sep 2026 | PRER14A |
| 08 Sep 2026 | PRE 14A |
| 08 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells |
| 31 Aug 2026 | EFFECT |
| 28 Aug 2026 | CORRESP |
| 28 Aug 2026 | S-1/A |
| 26 Aug 2026 | UPLOAD |
| 20 Aug 2026 | S-1 |
| 14 Aug 2026 | 10-Q |
| 14 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 14 Aug 2026 | 10-Q/A |
| 14 Aug 2026 | 8-K: Non-Reliance on Previously Issued Financial Statements |
| 06 Aug 2026 | D |
| 31 Jul 2026 |
Form 4: Wong Hing C, Director
Bought 23,210 shares ($60K) |
Loading...
